Skip to main content
HLB SCIENCE Inc. logo

HLB SCIENCE Inc. — Investor Relations & Filings

Ticker · 343090 ISIN · KR7343090007 KO Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2025-05-09 Capital/Financing Update
Country KR South Korea
Listing KO 343090

About HLB SCIENCE Inc.

https://hlbscience.com/eng/index.php

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Recent filings

Filing Released Lang Actions
전환가액의조정 (제4회차)
Capital/Financing Update Classification · 100% confidence The document is a formal notice regarding the adjustment of the conversion price for convertible bonds (제4회차 전환사채). It details the change in conversion price, the number of convertible shares, and the methodology used for the adjustment due to market price fluctuations. This type of filing relates to the company's capital structure and financing instruments. According to the provided definitions, updates on financing activities and capital structure changes fall under the 'CAP' (Capital/Financing Update) category.
2025-05-09 Korean
본점소재지변경
Regulatory Filings Classification · 100% confidence The document is a short, formal announcement regarding a change in the company's registered office address (headquarters). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor does it relate to share transactions or dividends. As it is a general regulatory announcement regarding corporate administrative changes, it falls under the fallback category for regulatory filings.
2025-04-23 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회 결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director appointments, and remuneration limits. This matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-03-25 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and vesting conditions. This type of disclosure is a standard regulatory requirement for public companies to report changes in capital structure or equity-based compensation, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2025-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal notification titled '감사보고서 제출' (Submission of Audit Report) for HLB Science. It provides a summary of the audit opinion (unqualified/appropriate), key financial figures (assets, liabilities, net income), and the name of the accounting firm. While it contains financial data, it is a regulatory disclosure announcing the submission of the audit report to the exchange, rather than the full annual report itself. Therefore, it fits the definition of an Audit Report/Information (AR) filing. FY 2024
2025-03-17 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for HLB Science, covering the fiscal year 2024 (Jan 1, 2024 to Dec 31, 2024). It contains detailed company information, management structure, capital changes, and business descriptions, which are standard components of an Annual Report (10-K equivalent in the Korean regulatory context). FY 2024
2025-03-17 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.